RESOURCE LIBRARY

Advancing medicine through scientific ingenuity

RESOURCE LIBRARY

Advancing medicine science through scientific ingenuity

At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.

Filter by

CLEAR
Thursday, May 14, 2026
Society for Investigative Dermatology Annual Meeting
BTK degradation by bexobrutideg suppresses B cell activation and FcεRI-mediated degranulation in preclinical models of chronic spontaneous urticaria
Tuesday, April 21, 2026
AACR 2026
Discovery and Characterization of CBL-B Intramolecular Glue Inhibitors That Increase T Cell Activation and Suppress Tumor Growth
Monday, April 20, 2026
AACR 2026
NRX-4972, a selective, oral, Aurora kinase A degrader, demonstrates increased efficacy in an SCLC tumor model, and greater in vitro synergy than an AURKA inhibitor
Monday, April 20, 2026
AACR 2026
NRX-0305: an Orally Bioavailable, CNS Penetrant, Pan-Mutant BRAF Degrader Demonstrates Robust Efficacy in Intracranial Models of Melanoma Brain Metastasis and Primary Glioma
Monday, April 20, 2026
AACR 2026
NRX-0305 is an Orally Bioavailable, Pan-Mutant BRAF Degrader that Exhibits Single Agent and Combination Efficacy with MEKi or anti-EGFR Across Class 1/2/3 BRAF Mutant Cancers
Tuesday, March 24, 2026
ACS 2026
Combinatorial Optimization of Degrader-Antibody Conjugates Enabled by Automation
Monday, December 8, 2025
American Society of Hematology
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in Patients with Waldenström Macroglobulinemia: Updated Results from an Ongoing Phase 1a/b Study
Saturday, December 6, 2025
American Society of Hematology
Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial
Saturday, December 6, 2025
The 67th ASH Annual Meeting
Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation
Friday, November 7, 2025
SITC 2025
NX-1607: Translational Insights From a First-in-Human Study of an Oral CBL-B Inhibitor in Advanced Solid Tumors
hide2